Skip Therapeutics develops personalized RNA-based treatments for rare genetic diseases in directly identified patients and patient cohorts using a novel, proprietary computational engine. The companys bioinformatic pipeline analyzes disease-causing mutations and recognizes the best available molecular strategy to restore protein function using splice-modulating antisense oligonucleotides (ASOs). The analysis of mutation data at scale enables identification of treatable patient cohorts and optimizes target selection, with top candidates from the computational analyses experimentally validated and pursued for therapeutic development. Skip Therapeutics operates from the FutuRx biotech incubator.